



2 July 2020

Concepta PLC
("Concepta" or the "Company")

Result of AGM

Concepta PLC (AIM: CPT), the innovative UK personalised healthcare company and developer of myLotus®, the UK's most accurate home-use fertility tracking and pregnancy self-testing system, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

Details of voting are provided below:

Resolution	For	Against
Resolution 1	107,315,949	86,504
Resolution 2	107,320,669	63,504
Resolution 3	106,115,669	1,266,784
Resolution 4	106,120,669	1,286,504
Resolution 5	106,070,949	1,336,504
Resolution 6	106,070,949	1,336,504
Resolution 7	106,120,949	1,286,504
Resolution 8	105,846,568	1,470,127
Resolution 9	104,660,762	2,655,653

Concepta plc

Penny McCormick, Chief Executive Officer
Maddy Kennedy, Chief Financial Officer

www.conceptapl.com

via Walbrook PR

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Tel: +44 (0)20 3368 3550

Novum Securities (Broker)

Colin Rowbury

Tel: +44 (0)20 7399 9400

Walbrook PR Ltd (Media & Investor Relations)

Paul McManus

Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com

Mob: +44(0)7980 541 893

About Concepta PLC (www.conceptapl.com)

Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.

myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.

The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2020.

myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.